In glimpse of tiny patient group, IN8bio’s ‘off-the-shelf’ gamma delta T cells remain durable

Lei Lei Wu

News Reporter

Seven months after dropping some very limited, but promising, data on three patients who received its gamma delta T cell treatment for leukemia, IN8bio revealed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In glimpse of tiny patient group, IN8bio’s ‘off-the-shelf’ gamma delta T cells remain durable

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Biotech industry worries over potential for RFK Jr. ally as FDA pick

GSK leaves biotech trade group BIO

Soft RSV sales reveal a vaccine market failing to catch post-Covid momentum

New Trump era could be a boon for biopharma M&A, dealmaking

Is there room for MASH drugs in a GLP-1 world?

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

In glimpse of tiny pa­tient group, IN8bio’s ‘off-the-shelf’ gam­ma delta T cells re­main durable

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

GSK leaves biotech trade group BIO

Soft RSV sales re­veal a vac­cine mar­ket fail­ing to catch post-Covid mo­men­tum

New Trump era could be a boon for bio­phar­ma M&A, deal­mak­ing

Is there room for MASH drugs in a GLP-1 world?

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

In glimpse of tiny patient group, IN8bio’s ‘off-the-shelf’ gamma delta T cells remain durable

Biotech industry worries over potential for RFK Jr. ally as FDA pick

Soft RSV sales reveal a vaccine market failing to catch post-Covid momentum

New Trump era could be a boon for biopharma M&A, dealmaking

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks